Transcriptional coactivator with PDZ-binding motif (TAZ) is a transcriptional coactivator involved in the differentiation of stem cell as well as the development of multiple organs. Recently, TAZ has also been identified as a major component of the novel Hippo-LATS tumor suppressor pathway and to function as an oncogene in breast cancer. We show for the first time that TAZ is an oncogene in non-small cell lung cancer (NSCLC). Our results show that TAZ is overexpressed in NSCLC cells and that lentivirus-mediated overexpression of TAZ in HBE135 immortalized human bronchial epithelial cells causes increased cell proliferation and transformation, which can be restored back to its original levels by knockdown of TAZ. In addition, short-hairpin RNA (shRNA)-mediated knockdown of TAZ expression in NSCLC cells suppresses their proliferation and anchorage-independent growth in vitro, and tumor growth in mice in vivo, which can be reversed by re-introduction of shRNA-resistant TAZ into TAZ-knockdown NSCLC cells. These results indicate that TAZ is an oncogene and has an important role in tumorigenicity of NSCLC cells. Therefore, TAZ may present a novel target for the future diagnosis, prognosis and therapy of lung cancer.
Introduction
Lung cancer is the most common cancer worldwide, killing 1.2 million people annually (World Health Organization, 2009) . Despite the advancement in surgical, radio-and chemo-therapies over the years, the 5-year survival rate of lung cancer remains o15% (Sun et al., 2007) , underscoring the aggressive nature of this disease. Of lung cancers diagnosed, over 80% are non-small cell lung cancer (NSCLC), which includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma (Yokota and Kohno, 2004) . In the past decades, although many tumor suppressor genes (for example, p53, Rb, p16 and so on) and oncogenes (EGFR, K-ras, Cyclin D and so on) important for the development of NSCLC have been identified; the majority of NSCLC patients are usually diagnosed during the later stages of lung cancer and die without successful treatment (Sekido et al., 2003; Yokota and Kohno, 2004; Dutt and Wong, 2006; Sato et al., 2007) . Therefore, the identification of new proteins responsible for NSCLC progression is critical for both early detection and the development of novel therapeutic approaches for the successful treatment of lung cancer.
TAZ, also called WW-domain containing transcription regulator 1 (WWTR1), is a WW-domain-containing transcriptional coactivator that activates many transcriptional factors, which have important roles in the development of various tissue in mammals (Wang et al., 2009) . TAZ has also been shown to regulate stem cell differentiation and renewal through modulation of the transcription factors PPARg, Runx2 and Smad (Hong et al., 2005; Varelas et al., 2008) . Moreover, TAZ knockout mice develop polycystic kidney disease and emphysema (Mitani et al., 2009; Tian et al., 2007) . Recently, TAZ has been identified as a component of an emerging Hippo-LATS tumor suppressor pathway that has important roles in regulating cell proliferation, apoptosis, tumor formation and organ size in both Drosophila and mammals (Harvey and Tapon, 2007; Saucedo and Edgar, 2007; Zhao et al., 2007 Zhao et al., , 2008 Zeng and Hong, 2008; Hergovich and Hemmings, 2009; Wang et al., 2009; Visser and Yang, 2010) . Significantly, we and others have shown that human homologs of Drosophila Hippo and LATS tumor suppressors, Mst2 and LATS1/2, can suppress tumor cell growth by phosphorylating and inhibiting TAZ and its paralog YAP (Zhao et al., 2007; Hao et al., 2008; Lei et al., 2008; Chow et al., 2010) . Most recently, enhanced expression of TAZ rather than YAP has been found in both breast cancer cell lines and tissues (Chan et al., 2008) . Moreover, overexpression of TAZ has been shown to cause enhanced cell proliferation and migration, transformation and the epithelial-mesenchymal transition (EMT) in human immortalized mammary epithelial cells, whereas knockdown of TAZ in breast cancer cells inhibits tumor formation (Chan et al., 2008) , suggesting that TAZ is a novel oncogene and may have important roles in the development of breast cancer. However, whether TAZ is also involved in the tumorigenesis of other types of cancer has not been explored. In this study, we have provided strong evidence that TAZ is a novel oncogene in NSCLC cells by using human lung cancer cell lines and in vivo mouse model.
Results and discussion

Overexpression of TAZ in NSCLC cells
We and others have recently found that overexpression of the LATS1 tumor suppressor inhibits lung cancer cell growth, whereas LATS2 is mutated or downregulated in NSCLC (Yang et al., 2001; Strazisar et al., 2009) , suggesting that LATS1/2 may be involved in lung tumorigenesis. Given that the oncogenes TAZ and YAP are the only identified downstream targets mediating the tumor-suppressing function of LATS (Visser and Yang, 2010) , we examined whether they are also dysregulated in lung cancers. As NSCLC accounts for over 80% of lung cancers (Yokota and Kohno, 2004) , we investigated whether TAZ and YAP are involved in the development of NSCLC. We first examined the expression of TAZ and YAP proteins by western blot using several lung cell lines, including 2 normal human bronchial epithelial (HBE) cells derived from primary lung tissue, 3 immortalized but nontumorigenic HBE cell lines and 11 tumorigenic NSCLC cell lines. Most significantly, we found that TAZ is relatively low in all normal (HBE154 and HBE158) and immortalized HBE cell lines (HBE135, BEAS-2B and NL20), but is overexpressed in 9 of 11 (81%) tumorigenic NSCLC cell lines examined ( Figure 1 ). However, YAP is consistently expressed in 15 of 16 HBE cell lines examined ( Figure 1 ). Moreover, phosphorylated (inactivated) forms of YAP (pYAP) and TAZ (pTAZ) are expressed at intermediate and at low levels, respectively, in all HBE cell lines ( Figure 1 ). Interestingly, TAZ was not detected in the large cell carcinoma cell lines examined, QU-DB and SK-luCi-6 ( Figure 1 ). Examination of TAZ levels using other large cell carcinoma cell lines will finally confirm whether TAZ is detectable in large cell carcinoma cells.
These results are consistent with the previous findings in which TAZ rather than YAP is overexpressed in breast cancer cell lines (Chan et al., 2008) . As enhanced expression of oncogenes has frequently been found in NSCLC cells (Lo et al., 2008; Bass et al., 2009; Brambilla and Gazdar, 2009; Cai et al., 2010; Kim et al., 2010) , our results strongly suggest that TAZ rather than YAP may be an oncogene involved in the development of NSCLC. However, by immunohistochemical analysis of YAP in NSCLC tissues, Wang et al. (2010) have recently shown that high levels of YAP is significantly correlated with poor prognosis and lymph node metastasis in NSCLC. Nonetheless, consistent with our findings, they also found that YAP is highly expressed in most of NSCLC cells. As YAP was only examined in NSCLC cells rather than in normal and in immortalized HBE cells, it is unclear from their study whether YAP is activated in NSCLC cells. Given that YAP and TAZ have independent and overlapping functions (Wang et al., 2009) , it is possible that both YAP and TAZ may be involved in lung tumorigenesis in vivo. Further examination of TAZ levels, using clinical NSCLC patient tissues by immunohistochemistry, will finally establish TAZ as a novel prognostic or diagnostic biomarker for the development of NSCLC.
Overexpression of TAZ induces increased cell proliferation and transformation
To further confirm that TAZ is indeed a novel oncogene in lung cancer, we first investigated the effects of overexpressing TAZ in a TAZ-low, immortalized, nontumorigenic cell line, HBE135 (Figure 2a ) by lentivirusmediated infection of these cells with vector alone (WPI) or HA-tagged TAZ. Significantly, we found that, compared with HBE135 cells infected by WPI, overexpression of TAZ in HBE135 cells caused enhanced cell proliferation (Figure 2b ). Moreover, HBE135 cells overexpressing TAZ rather than WPI acquired anchorage-independent growth on soft agar, a phenotype of transformed tumor cells (Figures 2c-d) . To eliminate the possibility that enhanced cell proliferation and transformation of HBE135 cells are caused by nonspecific effect of the lentivirus rather than TAZ overexpression, we also knocked down overexpressed TAZ in HBE135-TAZ cells back to its original levels by short-hairpin RNA (shRNA) against TAZ (Figure 2a) . Significantly, knockdown of TAZ reversed the TAZ-induced increase in cell proliferation and transformation (Figures 2b-d) , suggesting that TAZ-induced phenotypes are specific. We also subcutaneously injected TAZ-overexpressing HBE135 cells into immunocompromised nude mice to see whether they can form tumors. No tumor formation was detected at 2 months after injection (data not Figure 1 Enhanced expression of TAZ in NSCLC cells. About 10 mg of cell lysate extracted from HBE cells were subjected to western blot using rabbit polyclonal anti-TAZ (Cell Signaling, Danvers, MA, USA), anti-YAP (Santa Cruz, Santa Cruz, CA, USA), or mouse monoclonal anti-b-actin (Sigma, Oakville, Canada) antibodies. The levels of b-actin were used as internal protein loading controls.
TAZ as an oncogene in NSCLC Z Zhou et al shown), indicating that overexpression of TAZ alone is insufficient to confer full tumorigenecity of HBE cells. The enhanced cell proliferation and transformation caused by TAZ overexpression in HBE cells are similar to those induced by TAZ overexpression in immortalized mammary cells (Chan et al., 2008; Lei et al., 2008) . However, different from mammary cells, overexpression of TAZ in HBE cells was unable to induce EMT and reduced E-cadherin levels (data not shown), which is often associated with cancer cell invasion and metastasis (Wu and Zhou, 2008) . This suggests that TAZ may promote tumor formation rather than metastasis during lung tumorigenesis. Moreover, consistent to our findings, overexpression of other oncogenes, such as K-ras, the most commonly activated oncogene in NSCLC, or downregulation of tumor suppressor gene p53 in immortalized HBE cells, also caused increased cell proliferation and anchorage-independent growth on soft agar but not tumor formation or metastasis in nude mice (Sato et al., 2006) . These studies suggest that, like K-ras, whereas TAZ alone can cause partial transformation of HBE cells, it may function in concert with other oncogenes or tumor suppressor genes to cause full-malignant transformation in these cells. Therefore, examination of interactions between TAZ and other oncogenes or tumor suppressor genes in lung tumorigenesis will be very important in understanding the roles of TAZ in lung cancers.
Knockdown of TAZ in NSCLC cells reduce tumorigenic phenotypes
To examine whether elevated levels of TAZ directly contribute to the tumorigenecity of NSCLC cells, we knocked down TAZ in two TAZ-high NSCLC cell lines, A549 and H1299 (Figure 1 ), by infection with lentivirus-expressing shRNAs targeting different regions of TAZ (shTAZ1 and shTAZ2, Open Biosystems, Huntsville, AL, USA) (Figures 3a and c) . shRNA lentiviral vector pLKO.1 was used as a negative control. Significantly, knockdown of TAZ in A549 or H1299 cells by both shTAZs can significantly suppress tumor cell proliferation (Figures 3a-d) , suggesting that increased expression of TAZ in NSCLC cells is important for maintaining high tumor cell growth. To further confirm that the effect of TAZ knockdown on cell proliferation is not an off-target or viral effect, we also transduced A549-shTAZ-1 cells with lentivirus-expressing TAZ mutant cDNA, which has silent mutations in the shTAZ-1 targeting sequence, and is therefore resistant (Hao et al., 2008) . Cell lysates extracted from established cells were subjected to western blot as described in Figure 1 . (b) Cell proliferation analysis. Triplicate of 4 Â 10 4 cells were seeded into each well of a 24-well plate. Cell numbers were counted on days 1, 2, 3, 4, 5 and 6 after seeding. The experiments were repeated at least three times. The mean and s.d. of three independent experiments are shown. Statistical analysis using Student's t-test shows that cell numbers for HBE135 cells-overexpressing TAZ are significantly higher than those expressing WPI vector or TAZ-shTAZ-1 at days 4, 5 and 6 after seeding (*Po0.01). (c) Soft-agar assay. About 2 Â 10 4 cells were mixed with 0.4% agarose in growth media and overlay on 0.8% agarose in a 35 mm plate. Colony formation was examined by staining colonies with 0.005% crystal violet. Pictures were taken using TE200 Nikon Inverted Fluorescent Microscope (Nikon, Montreal, Canada). (d) Quantitation of soft-agar assays. Colony number was counted using Bio-Rad Gel Doc System (Bio-Rad, Mississauga, Canada). The experiments were repeated three times. The mean and s.d. of three independent experiments are shown. Statistical analysis using Student's t-test shows that cell number for TAZ-overexpressed HBE135 cells are significantly higher than those expressing WPI vector or TAZ-shTAZ-1 (Po0.01).
TAZ as an oncogene in NSCLC Z Zhou et al to shTAZ-1-induced TAZ degradation (Figure 3e) . Significantly, restoration of TAZ in TAZ-knockdown A549 cells reversed the cell growth inhibition induced by shTAZ-1 (Figure 3f) , suggesting that the reduced cell proliferation induced by shTAZ is due to the reduction of TAZ in NSCLC cells.
To investigate whether TAZ is also important for the tumorigenecity of NSCLC cells in vitro and in vivo, we used soft agar and nude mice assays, respectively. Compared with A549 cells expressing pLKO.1 lentiviral vector control, A549 cells with TAZ knockdown (shTAZ1 and shTAZ2) exhibited a significant reduction in anchorage-independent growth on soft agar in vitro and tumor growth in nude mice in vivo (Figures 4a-c) . These effects are not caused by off-target effects of shTAZ because the reduced anchorage-independent growth and tumor formation in nude mice, caused by shTAZ, can be completely reversed by re-introducting the shRNAresistant TAZ mutant cDNA back into A549-shTAZ-1 cells (shTAZ-1/TAZ mutant cDNA) (Figures 4a-c) . Together, these studies strongly suggest that overexpression of TAZ is vital for the tumorigenesis of NSCLC cells. Tremendous progress has been made toward understanding the roles of the emerging Hippo-LATS tumor suppressor pathway in the regulation of cell proliferation, cell death and cell migration. However, it is largely unknown how this pathway is involved in specific human cancers (Pan, 2007; Zeng and Hong, 2008; Zhao et al., 2008; Visser and Yang, 2010) . Our studies provided the first in vitro and in vivo evidence that TAZ is a novel oncogene in lung cancer, and that enhanced levels of TAZ may be responsible for the tumorigenesis of NSCLC cells. Consistent with our findings that TAZ functions as an oncogene in NSCLC, the LATS2 tumor suppressor gene, a negative regulator of TAZ and a central factor of the Hippo-LATS pathway was also found to be downregulated in the majority of NSCLC (Strazisar et al., 2009) . In addition, similar to TAZ, a recent study showed that YAP can function as an oncogene in lung cancer, as knockdown of YAP in NSCLC cells reduced cell proliferation and as anchorage-independent growth (Wang et al., 2010) . As TAZ and YAP are paralogs and can interact with each other (Wang et al., 2010) , it is possible that knockdown of either TAZ or YAP can reduce their oncogenic function in NSCLC cells. Together, the research findings from the current study and those of others strongly suggest that dysregulation of the Hippo-LATS signaling pathway may contribute to tumorigenesis in NSCLC. Future development of reagents targeting this signaling pathway will be promising therapeutic strategies for the successful treatment of NSCLC.
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